---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-012220"
form_type: "8-K"
ticker: "EVFM"
cik: "0001618835"
company_name: "Evofem Biosciences, Inc."
filed_at: "2023-04-14T23:59:59+00:00"
generated_at: "2026-06-17T01:57:32.229489+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Evofem appoints Ivy Zhang as CFO and Secretary; interim CFO Albert Altro departs

## Summary
- Albert Altro's interim CFO appointment terminated immediately April 13; Traverse engagement to end by April 30.
- Saundra Pelletier resigned as Secretary but remains CEO; Ivy Zhang appointed CFO and Secretary effective April 13.
- Ivy Zhang receives annual base salary of $410,000, eligible for bonus up to 40% of salary, and standard benefits.
- Zhang previously served as Evofem's Controller (2020-2022) and Director of SEC Reporting; returns from HUYABIO.
- CEO Saundra Pelletier stated goal to achieve quarterly EBITDA breakeven by end of 2023 with Zhang's leadership.

## SEC filing metadata
- accession: 0001493152-23-012220
- form_type: 8-K
- ticker: EVFM
- cik: 0001618835
- company_name: Evofem Biosciences, Inc.
- filed_at: 2023-04-14T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1618835/000149315223012220/0001493152-23-012220-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1618835/000149315223012220/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-012220
- JSON: https://secwatch.observer/filing/0001493152-23-012220.json
- Plain text: https://secwatch.observer/filing/0001493152-23-012220.txt

## Key facts
- Executive change
  Ivy Zhang was appointed as Chief Financial Officer and Secretary at Evofem Biosciences, Inc..
  - Action: appointed
  - Role: Chief Financial Officer and Secretary
  source text: Ivy Zhang was appointed as the Chief Financial Officer and Secretary of the Company, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1618835/000149315223012220/0001493152-23-012220-index.htm
- Executive change
  Albert Altro was terminated as interim Chief Financial Officer at Evofem Biosciences, Inc..
  - Action: terminated
  - Role: interim Chief Financial Officer
  source text: Albert Altro’s appointment as the Company’s interim Chief Financial Officer terminated, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1618835/000149315223012220/0001493152-23-012220-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.